WO2024175020 - ANTI-IL2RA ANTIBODIES AND USES THEREOF
National phase entry:
Publication Number
WO/2024/175020
Publication Date
29.08.2024
International Application No.
PCT/CN2024/077898
International Filing Date
21.02.2024
Title **
[English]
ANTI-IL2RA ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-IL2RA ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
YANG, Yongfei
ZHANG, Wenjiao
CAO, Shuzhen
GUAN, Zeliang
ZHANG, Jing
LIU, Yacui
Priority Data
PCT/CN2023/077623
22.02.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3225 | |
| EPO | Filing, Examination, Granting | 41633 | |
| Japan | Filing, Examination, Granting | 3576 | |
| South Korea | Filing, Examination, Granting | 4876 | |
| USA | Filing, Examination, Granting | 19540 |
Total:
72,850
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided are anti-IL2RA (interleukin-2 receptor alpha chain) antibodies, antigen-binding fragments, and the uses thereof.[French]
L'invention concerne des anticorps anti-IL2RA (chaîne alpha du récepteur de l'interleukine-2), des fragments de liaison à l'antigène et leurs utilisations.